<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02096042</url>
  </required_header>
  <id_info>
    <org_study_id>2013-0706</org_study_id>
    <secondary_id>NCI-2014-01114</secondary_id>
    <nct_id>NCT02096042</nct_id>
  </id_info>
  <brief_title>Phase I/II - Brentuximab/5-Azacytidine in Acute Myeloid Leukemia (AML)</brief_title>
  <official_title>A Phase I/II Study of Weekly Schedule Of Brentuximab Vedotin Alone and In Combination With 5-Azacytidine In Cluster of Differentiation Antigen (CD30)-Positive Relapsed/Refractory Acute Myeloid Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Seagen Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This clinical research study is made up of 3 phases: a Pilot Phase, Phase 1, and Phase 2.&#xD;
&#xD;
      The goal of the Pilot Phase is to learn how safe it is to give the study drug brentuximab&#xD;
      vedotin to patients with AML. The goal of Phase 1 is to learn more about the safety of the&#xD;
      combination of brentuximab vedotin with azacytidine. The goal of Phase 2 is to learn if the&#xD;
      combination of brentuximab vedotin and azacytidine can help to control AML.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study Groups:&#xD;
&#xD;
      If you are found to be eligible to take part in this study, you will be assigned to a study&#xD;
      group based on when you join this study. Up to 3 groups of 3-6 participants will be enrolled&#xD;
      in the Pilot Phase, up to 3 groups of 3-6 participants will be enrolled in Phase I of the&#xD;
      study, and up to 25 participants will be enrolled in Phase II.&#xD;
&#xD;
      If you are enrolled in the Pilot Phase, the dose of brentuximab vedotin you receive will&#xD;
      depend on when you joined this study. The first group of participants will receive the&#xD;
      highest dose level of brentuximab vedotin. If intolerable side effects are seen, up to 2 more&#xD;
      groups will be enrolled and will receive a lower dose of brentuximab vedotin than the group&#xD;
      before it. If intolerable side effects are not seen, the next phase of the study will begin.&#xD;
&#xD;
      If you are enrolled in Phase I, the dose of brentuximab vedotin you receive will depend on&#xD;
      when you joined this study. The first group of participants will receive a lower dose level&#xD;
      of brentuximab vedotin than the highest one that was tolerated in the Pilot Phase, and will&#xD;
      also receive azacitidine. If intolerable side effects are seen, up to 2 more groups will be&#xD;
      enrolled and will receive a lower dose of brentuximab vedotin than the group before it. If&#xD;
      intolerable side effects are not seen, the next phase of the study will begin.&#xD;
&#xD;
      If you are enrolled in Phase 2, you will receive brentuximab vedotin at the highest dose that&#xD;
      was tolerated in Phase 1.&#xD;
&#xD;
      All participants in Phases 1 and 2 will receive the same dose level of azacytidine.&#xD;
&#xD;
      Study Drug Administration:&#xD;
&#xD;
      If you are found to be eligible to take part in this study, you will receive brentuximab&#xD;
      vedotin by vein over 30 minutes on Days 1, 8, and 15 of each 28-day study cycle. If the&#xD;
      disease appears to get better, or after cycle 4, the dose and schedule of brentuximab vedotin&#xD;
      may be changed to monthly rather than weekly doses.&#xD;
&#xD;
      If you are in Phase 1 or Phase 2, you will also receive azacytidine by vein or as an&#xD;
      injection under the skin on Days 1-7 of each cycle.&#xD;
&#xD;
      You may be given standard drugs to help decrease the risk of side effects. You may ask the&#xD;
      study staff for information about how the drugs are given and their risks.&#xD;
&#xD;
      Study Visits:&#xD;
&#xD;
      On Day 1 of each cycle:&#xD;
&#xD;
        -  You will have a physical exam.&#xD;
&#xD;
        -  Blood (about 2-3 tablespoons) will be drawn for routine tests.&#xD;
&#xD;
        -  You will have an EKG.&#xD;
&#xD;
        -  Every 3 Cycles (Cycles 3, 6, 9, and so on), if you can become pregnant, blood (about 1&#xD;
           teaspoon) or urine will be collected for a pregnancy test.&#xD;
&#xD;
      On Days 8 and 22 of Cycle 1, blood (about 2-3 tablespoons) will be drawn for routine tests.&#xD;
&#xD;
      On Day 15 of Cycle 1:&#xD;
&#xD;
        -  You will have a physical exam.&#xD;
&#xD;
        -  Blood (about 2-3 tablespoons) will be drawn for routine tests.&#xD;
&#xD;
      On Day 28 of Cycle 1, then Day 1 of every 2 cycles after that (Cycles 3, 5, 7, and so on),&#xD;
      you will have a bone marrow biopsy and/or aspirate to check the status of the disease. After&#xD;
      any point that the disease appears to get better, this will be done every 3-4 cycles, or&#xD;
      whenever your doctor thinks it is needed.&#xD;
&#xD;
      Length of Treatment:&#xD;
&#xD;
      You may receive the study drug for up to 12 cycles. You will no longer be able to receive the&#xD;
      study drug(s) if the disease gets worse, if intolerable side effects occur, or if you are&#xD;
      unable to follow study directions.&#xD;
&#xD;
      Your participation on the study will be over after the end-of-study visit.&#xD;
&#xD;
      End-of-Study Visit:&#xD;
&#xD;
      About 28 days after your last dose of study drug, you will have an end-of-study visit:&#xD;
&#xD;
        -  You will have a physical exam.&#xD;
&#xD;
        -  Blood (about 2-3 tablespoons) will be drawn for routine tests.&#xD;
&#xD;
        -  You will have an EKG to check your heart function.&#xD;
&#xD;
        -  You may have a bone marrow biopsy and/or aspirate to check the status of the disease.&#xD;
&#xD;
        -  If you can become pregnant, blood (about 1 teaspoon) or urine will be collected for a&#xD;
           pregnancy test.&#xD;
&#xD;
      If the End-of-Study Visit occurs within 21 days of your last dose, you will be called by a&#xD;
      member of the study team about 30-37 days after your last dose of study drug. You will be&#xD;
      asked how you are feeling and about any side effects you may be having. This call will last&#xD;
      about 5 minutes.&#xD;
&#xD;
      This is an investigational study. Brentuximab vedotin is FDA approved and commercially&#xD;
      available for the treatment of certain types of lymphoma after previous treatments have&#xD;
      failed. Its use in combination with azacitidine is investigational. Azacytidine is FDA&#xD;
      approved and commercially available for the treatment of myelodysplastic syndrome (MDS) and&#xD;
      chronic myelomonocytic leukemia (CMML).&#xD;
&#xD;
      The study doctor can explain how the study drug(s) are designed to work.&#xD;
&#xD;
      Up to 61 patients will take part in this study. All will be enrolled at MD Anderson.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Slow accrual.&#xD;
  </why_stopped>
  <start_date type="Actual">April 2014</start_date>
  <completion_date type="Actual">August 2016</completion_date>
  <primary_completion_date type="Actual">August 2016</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Tolerated Dose (MTD) of Brentuximab Vedotin in Combination With 5-Azacytidine</measure>
    <time_frame>After 1, 28 day cycle</time_frame>
    <description>MTD defined as maximum dose at which &lt;33% of patients experience a dose-limiting toxicity (DLT) during cycle 1.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall Response Rate</measure>
    <time_frame>Response assessed after four 28-day cycles, up to 120 days</time_frame>
    <description>Response defined as number of participants with complete response (CR), CR with incomplete platelet recovery (CRp), CR with insufficient hematological recovery (CRi) or partial remission (PR).</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1</enrollment>
  <condition>Leukemia</condition>
  <arm_group>
    <arm_group_label>Brentuximab Vedotin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pilot Phase: Starting dose of Brentuximab Vedotin 1.2 mg/kg intravenous (IV) infusion over approximately 30 minutes on days 1, 8, and 15 of each 28-day cycle (+/- 3 days).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Brentuximab Vedotin + 5-Azacytidine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Phase I Dose-Escalation Phase: Starting dose of Brentuximab Vedotin 1.0 mg/kg IV (starting dose level 1), or one-dose level lower than the established MTD if the pilot portion of the study establishes a lower MTD, infusion over approximately 30 minutes on days 1, 8, and 15 of each 28-day cycle. All patients receive 5-azacytidine at 75 mg/m2/day by vein or subcutaneously on days 1-7 every 28 days.&#xD;
Phase II Dose-Expansion Phase: Patients receive Brentuximab Vedotin at MTD from dose-escalation phase by vein on Days 1, 8, and 15 of each 28-day cycle. Patients receive 5-Azacytidine at 75 mg/m2/day by vein or subcutaneously on days 1-7 every 28 days. Patients can receive up to a total of 12 cycles of treatment (weekly + monthly combined).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Brentuximab Vedotin</intervention_name>
    <description>Pilot Phase: Starting dose of Brentuximab Vedotin 1.2 mg/kg intravenous (IV) infusion over approximately 30 minutes on days 1, 8, and 15 of each 28-day cycle.&#xD;
Phase I Dose-Escalation Phase: Starting dose of Brentuximab Vedotin 1.0 mg/kg IV (starting dose level 1), or one-dose level lower than the established MTD if the pilot portion of the study establishes a lower MTD, infusion over approximately 30 minutes on days 1, 8, and 15 of each 28-day cycle.&#xD;
Phase II Dose-Expansion Phase: Patients receive Brentuximab Vedotin at MTD from dose-escalation phase by vein on Days 1, 8, and 15 of each 28-day cycle.</description>
    <arm_group_label>Brentuximab Vedotin</arm_group_label>
    <arm_group_label>Brentuximab Vedotin + 5-Azacytidine</arm_group_label>
    <other_name>SGN-35</other_name>
    <other_name>Adcetris</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5-Azacytidine</intervention_name>
    <description>Phase I Dose-Escalation Phase and Phase II Dose-Expansion Phase: 5-Azacytidine at 75 mg/m2/day by vein or subcutaneously on days 1-7 every 28 days.</description>
    <arm_group_label>Brentuximab Vedotin + 5-Azacytidine</arm_group_label>
    <other_name>Azacytidine</other_name>
    <other_name>Azacitidine</other_name>
    <other_name>5-aza</other_name>
    <other_name>Vidaza</other_name>
    <other_name>5-AZC</other_name>
    <other_name>AZA-CR</other_name>
    <other_name>Ladakamycin</other_name>
    <other_name>NSC-102816</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Histologically or cytologically confirmed AML, other than acute promyelocytic&#xD;
             leukemia, as defined by the 2008 World Health Organization (WHO) criteria that is&#xD;
             relapsed or refractory to standard chemotherapy. Note: Newly-diagnosed AML patients&#xD;
             who are 60 years or older and are not candidates for or have refused standard&#xD;
             chemotherapy are also eligible for this trial.&#xD;
&#xD;
          2. AML blasts must express CD30 (&gt;/=10% expression as assessed by flow-cytometry or 2+&#xD;
             expression by immunohistochemistry) (whenever possible CD30 expression will be&#xD;
             assessed by both methods)&#xD;
&#xD;
          3. Age 18 years or older&#xD;
&#xD;
          4. Eastern Cooperative Oncology Group (ECOG) Performance Status score of &lt;/=3&#xD;
&#xD;
          5. The following baseline laboratory data: Serum bilirubin &lt;/=1.5 x upper limit of normal&#xD;
             (ULN) or &lt;/= 3 x ULN for patients with Gilbert's disease; Serum creatinine &lt;/=1.5 x&#xD;
             ULN AND creatinine clearance &gt;30 ml/min; Alanine aminotransferase (ALT) and aspartate&#xD;
             aminotransferase (AST) &lt;/=3 x ULN&#xD;
&#xD;
          6. Females of childbearing potential must have a negative serum or urine beta human&#xD;
             chorionic gonadotrophin (beta-hCG) pregnancy test result within 14 days prior to the&#xD;
             first dose of brentuximab vedotin and must agree to use an effective contraception&#xD;
             method during the study and for 30 days following the last dose of study drug. Females&#xD;
             of non- childbearing potential are those who are postmenopausal greater than 1 year or&#xD;
             who have had a bilateral tubal ligation or hysterectomy.&#xD;
&#xD;
          7. Males who have partners of childbearing potential must agree to use an effective&#xD;
             contraceptive method during the study and for 30 days following the last dose of study&#xD;
             drug&#xD;
&#xD;
          8. Patients or their legally authorized representative must provide written informed&#xD;
             consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. History of another primary invasive malignancy that has not been definitively treated&#xD;
             or in remission for at least 2 years. Patients with non-melanoma skin cancers or with&#xD;
             carcinomas in situ are eligible regardless of the time from diagnosis (including&#xD;
             concomitant diagnoses).&#xD;
&#xD;
          2. Documented history of a cerebral vascular event (stroke or transient ischemic attack),&#xD;
             unstable angina, myocardial infarction, or cardiac symptoms consistent with New York&#xD;
             Heart Association Class III-IV within 6 months prior to their first dose of&#xD;
             brentuximab vedotin&#xD;
&#xD;
          3. Evidence of active cerebral/meningeal disease. Patients may have history of central&#xD;
             nervous system (CNS) leukemic involvement if definitively treated with prior therapy&#xD;
             and no evidence of active disease at the time of registration.&#xD;
&#xD;
          4. Previous treatment with any anti-CD30 directed therapy&#xD;
&#xD;
          5. Patients with previous allogeneic stem cell transplant (SCT) if they meet either of&#xD;
             the following criteria: &lt;100 days from allogeneic SCT, Acute or chronic&#xD;
             graft-versus-host disease (GvHD), or Receiving immunosuppressive therapy as treatment&#xD;
             for or prophylaxis against GvHD within the last 7 days&#xD;
&#xD;
          6. Patients with uncontrolled active infections (viral, bacterial, and fungal) are not&#xD;
             eligible.&#xD;
&#xD;
          7. Known to be positive for hepatitis B by surface antigen expression&#xD;
&#xD;
          8. Known to have active hepatitis C infection (positive by polymerase chain reaction or&#xD;
             on antiviral therapy for hepatitis C within the last 6 months)&#xD;
&#xD;
          9. Preexisting grade &gt;/=2 peripheral neuropathy&#xD;
&#xD;
         10. Patients with uncontrolled diabetes mellitus&#xD;
&#xD;
         11. Current therapy with other systemic anti-neoplastic or anti-neoplastic investigational&#xD;
             agents.&#xD;
&#xD;
         12. Chemotherapy (except hydroxyurea or emergent use of single-agent cytarabine for&#xD;
             cytoreduction), radiotherapy, biologics, and/or other treatment with immunotherapy&#xD;
             that is not completed 2 weeks prior to first dose of study drug, unless progressive&#xD;
             disease is documented. NOTE: Hydroxyurea will be allowed during the first cycle of&#xD;
             treatment&#xD;
&#xD;
         13. Females who are pregnant or lactating&#xD;
&#xD;
         14. Known hypersensitivity to any excipient contained in the drug formulation of&#xD;
             brentuximab vedotin&#xD;
&#xD;
         15. History of progressive multifocal leukoencephalopathy (PML)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nitin Jain, MBBS</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Texas MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>University of Texas MD Anderson Cancer Center Website</description>
  </link>
  <verification_date>August 2017</verification_date>
  <study_first_submitted>March 20, 2014</study_first_submitted>
  <study_first_submitted_qc>March 21, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 26, 2014</study_first_posted>
  <results_first_submitted>August 2, 2017</results_first_submitted>
  <results_first_submitted_qc>August 2, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">September 5, 2017</results_first_posted>
  <last_update_submitted>August 2, 2017</last_update_submitted>
  <last_update_submitted_qc>August 2, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 5, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Leukemia</keyword>
  <keyword>Acute Myeloid Leukemia</keyword>
  <keyword>AML</keyword>
  <keyword>CD30-Positive</keyword>
  <keyword>Relapsed</keyword>
  <keyword>Refractory</keyword>
  <keyword>Brentuximab Vedotin</keyword>
  <keyword>SGN-35</keyword>
  <keyword>Adcetris</keyword>
  <keyword>5-Azacytidine</keyword>
  <keyword>Azacytidine</keyword>
  <keyword>Azacitidine</keyword>
  <keyword>5-aza</keyword>
  <keyword>Vidaza</keyword>
  <keyword>5-AZC</keyword>
  <keyword>AZA-CR</keyword>
  <keyword>Ladakamycin</keyword>
  <keyword>NSC-102816</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Azacitidine</mesh_term>
    <mesh_term>Brentuximab Vedotin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment Period: April 24, 2014 to July 08, 2015. All recruitment done at The University of Texas MD Anderson Cancer Center.</recruitment_details>
      <pre_assignment_details>Study was terminated early due to low enrollment.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Brentuximab Vedotin</title>
          <description>Pilot Phase: Starting dose of Brentuximab Vedotin 1.2 mg/kg intravenous (IV) infusion over approximately 30 minutes on days 1, 8, and 15 of each 28-day cycle (+/- 3 days).</description>
        </group>
        <group group_id="P2">
          <title>Brentuximab Vedotin + 5-Azacytidine</title>
          <description>Phase I Dose-Escalation Phase: Starting dose of Brentuximab Vedotin 1.0 mg/kg IV (starting dose level 1), or one-dose level lower than the established MTD if the pilot portion of the study establishes a lower MTD, infusion over approximately 30 minutes on days 1, 8, and 15 of each 28-day cycle. 5-azacytidine at 75 mg/m2/day IV or subcutaneously on days 1-7 every 28 days.</description>
        </group>
        <group group_id="P3">
          <title>MTD Brentuximab Vedotin + 5-Azacytidine</title>
          <description>Phase II Dose-Expansion Phase: Brentuximab Vedotin at MTD from dose-escalation phase IV on Days 1, 8, and 15 of each 28-day cycle. 5-Azacytidine at 75 mg/m2/day IV or subcutaneously on days 1-7 every 28 days.Up to 12 cycles of treatment (weekly + monthly combined).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Disease Progression</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Brentuximab Vedotin</title>
          <description>Pilot Phase: Starting dose of Brentuximab Vedotin 1.2 mg/kg intravenous (IV) infusion over approximately 30 minutes on days 1, 8, and 15 of each 28-day cycle (+/- 3 days).</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="1"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Maximum Tolerated Dose (MTD) of Brentuximab Vedotin in Combination With 5-Azacytidine</title>
        <description>MTD defined as maximum dose at which &lt;33% of patients experience a dose-limiting toxicity (DLT) during cycle 1.</description>
        <time_frame>After 1, 28 day cycle</time_frame>
        <population>Study terminated early.</population>
        <group_list>
          <group group_id="O1">
            <title>Brentuximab Vedotin + 5-Azacytidine</title>
            <description>Phase I Dose-Escalation Phase: Starting dose of Brentuximab Vedotin 1.0 mg/kg IV (starting dose level 1), or one-dose level lower than the established MTD if the pilot portion of the study establishes a lower MTD, infusion over approximately 30 minutes on days 1, 8, and 15 of each 28-day cycle. 5-azacytidine at 75 mg/m2/day IV or subcutaneously on days 1-7 every 28 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Tolerated Dose (MTD) of Brentuximab Vedotin in Combination With 5-Azacytidine</title>
          <description>MTD defined as maximum dose at which &lt;33% of patients experience a dose-limiting toxicity (DLT) during cycle 1.</description>
          <population>Study terminated early.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Overall Response Rate</title>
        <description>Response defined as number of participants with complete response (CR), CR with incomplete platelet recovery (CRp), CR with insufficient hematological recovery (CRi) or partial remission (PR).</description>
        <time_frame>Response assessed after four 28-day cycles, up to 120 days</time_frame>
        <population>Study was stopped with only one participant; no analysis done on outcome.</population>
        <group_list>
          <group group_id="O1">
            <title>Brentuximab Vedotin</title>
            <description>Pilot Phase: Starting dose of Brentuximab Vedotin 1.2 mg/kg intravenous (IV) infusion over approximately 30 minutes on days 1, 8, and 15 of each 28-day cycle (+/- 3 days).</description>
          </group>
          <group group_id="O2">
            <title>Brentuximab Vedotin + 5-Azacytidine</title>
            <description>Phase I Dose-Escalation Phase: Starting dose of Brentuximab Vedotin 1.0 mg/kg IV (starting dose level 1), or one-dose level lower than the established MTD if the pilot portion of the study establishes a lower MTD, infusion over approximately 30 minutes on days 1, 8, and 15 of each 28-day cycle. 5-azacytidine at 75 mg/m2/day IV or subcutaneously on days 1-7 every 28 days.</description>
          </group>
          <group group_id="O3">
            <title>MTD Brentuximab Vedotin + 5-Azacytidine</title>
            <description>Phase II Dose-Expansion Phase: Brentuximab Vedotin at MTD from dose-escalation phase IV on Days 1, 8, and 15 of each 28-day cycle. 5-Azacytidine at 75 mg/m2/day IV or subcutaneously on days 1-7 every 28 days.Up to 12 cycles of treatment (weekly + monthly combined).</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Response Rate</title>
          <description>Response defined as number of participants with complete response (CR), CR with incomplete platelet recovery (CRp), CR with insufficient hematological recovery (CRi) or partial remission (PR).</description>
          <population>Study was stopped with only one participant; no analysis done on outcome.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse event collection for first 28-day cycle.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Brentuximab Vedotin</title>
          <description>Pilot Phase: Starting dose of Brentuximab Vedotin 1.2 mg/kg intravenous (IV) infusion over approximately 30 minutes on days 1, 8, and 15 of each 28-day cycle (+/- 3 days).</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>CTCAE (4.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Urinary Tract Infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Pain - extremity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Erythema Multiforme</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Nitin Jain, MD/Assistant Professor, Leukemia</name_or_title>
      <organization>The University of Texas (UT) MD Anderson Cancer Center</organization>
      <phone>713-792-7734</phone>
      <email>CR_Study_Registration@mdanderson.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

